Semaglutide and GLP-1 analogues as weight-loss agents-Reference-Cited by-同舟云学术

Semaglutide and GLP-1 analogues as weight-loss agents

Published:2018-08 Issue:10148 Volume:392 Page:615-616
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Kluger Aaron Y,McCullough Peter A

Publisher

Elsevier BV

Subject

General Medicine

Reference4 articles.

1. New vistas for the treatment of obesity: turning the tide against the leading cause of morbidity and cardiovascular mortality in the developed world;Lepor;Rev Cardiovasc Med,2014

2. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity: executive summary;Garvey;Endocr Pract,2016

3. Regarding obesity as a disease: evolving policies and their implications;Kyle;Endocrinol Metab Clin North Am,2016

4. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial;O'Neil;Lancet,2018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study;BMC Medicine;2024-05-29

2. Preparation of semaglutide long-acting injectable microcapsules with physicochemical properties, long-term stability, and pharmacokinetics and pharmacodynamics;Journal of Pharmaceutical Investigation;2024-05-29

3. Decisional Dilemmas in Psychiatry and the Need for Informative Pragmatic Trials;Psychiatric Annals;2022-01

4. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms;Molecular Metabolism;2021-04

5. Design and characterization of a surfactant‐conjugated, long‐acting, balanced GLP ‐1/glucagon receptor dual agonist;Peptide Science;2021-01-22